Clinical reviewer: Dr. Sarah Boss, MD

COGNIFUL, part of THE BALANCE GROUP, publishes this guide. It compares selected European medical and addiction services with our own possible residential role after medical needs are addressed. The comparison is not an independent ranking of equivalent luxury facilities. Each provider’s exact program, admission criteria, location and medical scope must be confirmed for the person.

The word detox may refer to withdrawal management, but a person can also need treatment for intoxication, a substance use disorder, a prescribed-medication concern or another medical condition. Ask the assessing clinician to explain the actual problem and the recommended sequence. A fixed package offered before the substance and history are understood does not demonstrate an individualized clinical plan.

Provide an accurate account of all substances and medicines, including actual use, recent changes and previous treatment. Describe uncertain products as uncertain rather than assuming their contents. Include alcohol, opioid medication and sedatives even if another drug is the main concern. A complete picture can change the required care level and the treatment that follows.

Previous overdose, severe withdrawal, seizures, hospital admissions and psychiatric crises should be disclosed. The person should not minimize the history to gain access to a preferred residence. If the assessment identifies a need for a hospital or specialist medical service first, that recommendation helps make the pathway appropriate. It is not a failure to qualify for a more comfortable setting.

The table shows different stages of care rather than identical treatment packages. Some providers describe hospital or medically assisted withdrawal services, while COGNIFUL is a residence considered after suitability review. The comparison does not establish that every organization accepts every substance, medical complication or international referral. Ask about the exact accepting unit and clinical plan.

If a provider has several sites, confirm which one supplies the service described. Medical assessment, detox, outpatient treatment and residential care may occur in different places. The person should know where each stage happens, who is responsible and whether the next service has accepted the handover. A familiar brand name is not a completed care arrangement.

For opioid use disorder, the CDC recommends medication treatment and advises against detoxification alone because of increased risks of returning to use and overdose. This clinical distinction is important when questioning any European program, even though specific prescribing systems differ. Ask how appropriate ongoing opioid treatment is provided or arranged rather than accept a promise that a short drug-free period completes care. [1]

The plan should name the responsible clinician or service and explain how treatment continues after discharge. If the residence does not prescribe directly, the external arrangement should be explicit. A person should not leave a medical unit with an essential treatment plan that the next provider has not agreed to support. Continuing care is part of the initial decision, not an optional detail to solve later.

Ask about overdose-prevention education and the relevant clinical support for the person and household. The CDC includes naloxone and education within opioid use disorder care. The appropriate professional should explain the individual plan. These questions help evaluate a service; they are not a substitute for assessment or a self-detox instruction. [1]

If prescription opioids are involved, pain also requires attention. A person can have a legitimate pain condition and a harmful pattern of use. Ask which professional coordinates both needs and how existing specialists participate with consent. The plan should not demand that pain be ignored in order to discuss addiction, or overlook harmful use because the first prescription was appropriate.

Regular prescribed benzodiazepine use can produce physical dependence without a substance use disorder. The joint guideline makes that distinction explicit. The assessment should determine whether the main need is medical review, treatment of harmful use, support for the original condition or several needs together. A general drug-detox label should not replace that reasoning. [2]

Benzodiazepines should not be stopped abruptly or reduced rapidly without an appropriate clinical plan because severe withdrawal, including seizures, can occur. Alcohol and opioids add serious interaction risks. Do not independently change or substitute medication to prepare for a program or a journey. The medical setting should follow the assessed risks and available support. [9]

The joint guideline recognizes that some medication changes take a prolonged period and may continue beyond a brief admission. Ask how a European provider handles that possibility and who will continue prescribing review afterward. The residential booking should not become a deadline for a medical process. The next service needs to understand and accept the plan before transfer. [2]

ASAM and AAAP guidance treats stimulant intoxication and withdrawal as specific clinical issues, with potential medical and psychiatric complications. Ask how the proposed program assesses current symptoms and determines whether hospital or acute psychiatric care is needed. A generic detox service designed around another substance does not establish the necessary expertise. [3]

The continuing treatment plan should explain what therapeutic work follows the medical phase. It may concern the pattern of use, coping, sleep, work or relationships, according to assessment. The program should identify concrete goals and professionals rather than offer only a period away from the person’s usual environment. A residence needs a defined clinical purpose beyond a change of scenery.

Where prescribed stimulants are involved, the original indication should remain part of assessment. The person should be able to discuss both benefits and harmful use without assuming that every prescription is inappropriate or that every difficulty is explained by addiction. The responsible clinician should determine the diagnosis and appropriate treatment pathway.

Several substances may be involved even when one is named in the inquiry. Ask who reconciles the complete history and coordinates medical decisions. Separate prescriptions or treatment plans can create uncertainty if no professional has the overall picture. The person should not be expected to decide which instruction takes priority when different services appear to disagree.

Describe alcohol, sedatives, pain medication, nonprescribed drugs and other relevant products honestly. The clinical team can assess significance; the client should not exclude information because it seems occasional or unrelated. If a product’s identity is unknown, the provider should explain what can be assessed and what remains uncertain rather than infer safety from an assumed name.

Mental health and physical health should be reviewed alongside substance use. A program advertising co-occurring care may still have limits around acute instability. Ask what it manages directly, what requires another service and how escalation works. The comparison should be based on those actual capabilities rather than a broad claim to treat everything under one roof.

Ask who performs the initial assessment, which professionals monitor care and what response is available if the condition changes. Distinguish onsite medical services from external appointments or referral arrangements. A clinician being associated with a provider does not establish continuous presence or a particular emergency capability. The proposal should describe the relevant arrangement for the actual program.

If breathing difficulty, suspected overdose, a seizure, severe confusion or immediate danger is present, urgent local medical help takes precedence. An international admissions process should not delay care. Once the person is stable, the next treatment stage can be considered with the appropriate professionals. [9]

Also ask what information is missing. A service may reasonably need records, examination or specialist review before confirming suitability. Acknowledging uncertainty and explaining how it will be resolved is more useful than promising a standard duration or outcome before assessment. The person should understand which decisions are confirmed and which remain conditional.

Confirm the actual prescribing and dispensing arrangements before travel. Do not assume that a medicine, formulation or prescription can be transferred unchanged between countries. Check the route’s requirements through the relevant authorities and clinicians. Where ongoing opioid or other medical treatment is essential, the accepting provider should be identified before the person leaves the previous service.

Records should include the current treatment, medical course and unresolved concerns. Agree secure information sharing and the language of the handover. The client should receive a usable explanation as well as professional documentation. They should not become the only link between several clinicians who have not communicated with one another.

Travel readiness should be assessed rather than inferred from discharge. If a medical recommendation changes, the itinerary and residential booking should be adaptable. A paid room or transport arrangement should not force the timing of a transfer. Ask who is responsible for any support needed between the medical service and the next setting.

COGNIFUL is based in Mallorca, Spain. Its suitability review considers substance use, withdrawal risk, current medical and psychiatric needs and the shared residential environment. If detoxification, acute care or another medical service is required, that comes first. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. [4] [8] The medical plan, prescribing responsibilities and any additional specialist support are confirmed individually.

For a person whose needs fit after stabilization, residential work may address the broader pattern of use, coping, relationships and preparation for life at home. Completion of detox does not automatically establish suitability. Ask what ongoing needs the residence can support, what remains external and which information is required before admission can be confirmed.

The residence takes a maximum of four clients at any time, each with a private suite. Clinical and bodywork sessions are individual. The residence, chef, personal manager, other holistic sessions, excursions and activities are shared. This describes the setting and session format. It does not establish hospital facilities, a fixed staffing ratio or superior outcomes. [8]

COGNIFUL Premier and Premier Plus both include assessment, an individual plan and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Follow-up under the base program is agreed individually. Typical residential stays are four to twelve weeks, reviewed for the person; the published fees and stay range concern residential care rather than medical detox. [8] View program fees

The written proposal should explain the actual clinical work, professionals, duration, inclusions and total cost. Separate medical detox, ongoing medication, external appointments and travel should be clarified. COGNIFUL is generally self-pay and does not bill insurers directly; reimbursement is not guaranteed. The choice between programs should follow the individual’s proposed work and support needs rather than price alone.

Continuing-care planning should identify accepted appointments and responsibilities in the country of return. The individual agreement determines what follow-up COGNIFUL delivers. Do not assume unrestricted cross-border prescribing or remote clinical access. If essential medical treatment continues, the local and residential teams should agree how it remains uninterrupted. [10]

The discharge document should support the next decision

Before agreeing to a sequence of European services, ask what information the first team will provide at the transition. A useful handover explains why the person was admitted, what was assessed, what treatment remains active and what still needs review. A certificate saying that a package was completed does not answer those clinical questions. The accepting professional should be able to identify the next appointment and the limits of the receiving setting.

Ask how the individual will participate in that discussion. They should understand the proposed plan in a language they can use, including whom to contact if an appointment is delayed or symptoms change. With consent, a family member may help organize records and transport, but should not become responsible for reconciling conflicting medical advice. Clarifying these ordinary practical details can reveal a gap that an attractive itinerary or a long list of therapies would leave hidden.

A medical detox quotation may cover assessment, monitoring and treatment during withdrawal. A residential quotation may cover a later period of accommodation and therapy. Ask for the scope of each, including additional services and what happens if the clinical recommendation changes. Similar marketing language does not make the products interchangeable.

Also compare the practical route after discharge. A lower price may not include the same follow-up, while a higher price does not guarantee a better clinical fit. Request actual appointments and accepted responsibilities rather than a generic promise of support. The complete pathway should be understandable to the person and family before they commit to several separate services.

• Which substance-related problems and health needs have been assessed?
• How does the medical approach change for opioids, benzodiazepines or stimulants?
• What services are onsite, external or not available in the proposed program?
• Which ongoing medical treatment is confirmed after the withdrawal phase?
• Who accepts the next stage, and what determines readiness for travel?

Ask the provider to explain the recommendation in relation to the person’s history. A clinically appropriate answer may involve local care, a hospital first or a coordinated sequence of services. The best comparison identifies those responsibilities before weighing comfort, privacy and destination.

Is there one best European detox program for all drugs?

No. Different substances and clinical situations require different medical pathways. The appropriate service follows assessment and the treatment needed afterward. [1] [2] [3]

Should opioid treatment end after detox?

For opioid use disorder, the CDC recommends medication treatment and advises against detoxification alone. The ongoing medical plan should be arranged before discharge. [1]

Can I stop sedatives before traveling?

Do not independently change prescribed medication for travel or admission. Abrupt benzodiazepine withdrawal can be dangerous. The responsible clinician should guide the plan. [9]

Does COGNIFUL perform onsite drug detox?

COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. Medical needs are reviewed before admission, and another provider may be required first. [4]

COGNIFUL admissions can explain residential suitability after necessary medical needs are addressed. Share the actual substances, current treatment and continuing requirements. Acute symptoms or immediate danger require local medical help before an international journey or residential booking. [8] [4]

1. Opioid use disorder: treating — Centers for Disease Control and Prevention.
2. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
3. Clinical Practice Guideline on the Management of Stimulant Use Disorder — American Society of Addiction Medicine and American Academy of Addiction Psychiatry.
4. Clinical scope, suitability and care coordination — COGNIFUL.
5. Psychiatry and Clinical Psychology Department — Clínica Universidad de Navarra.
6. Priory Hospital Roehampton — Priory.
7. Addiction disorders and dual diagnoses — Psychiatric University Hospital Zurich.
8. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
9. Benzodiazepine safety communication — US Food and Drug Administration.
10. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.